

VivaGel® BV launched in Asia

- VivaGel® BV has been launched in Asia by Mundipharma, under the brand name BETADINE™ BV Gel
- BETADINE™ BV Gel will be available Over-The-Counter
- Mundipharma is rolling out BETADINE™ BV Gel across Asia, as regulatory approvals are granted
- Regulatory activities are underway for multiple countries across other Mundipharma regions

Melbourne, Australia; 13 February 2020: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VivaGel® BV has been launched in Asia under the brand name BETADINE™ BV Gel. The product has initially been launched in South East Asia, with further roll-out in additional Asian countries, as regulatory approvals are granted.

BETADINE™ BV Gel will be available over-the-counter (OTC), without the need to see a doctor or obtain a prescription. Asia is the third region to launch VivaGel® BV and represents a large commercial opportunity with access to more than 1.5 billion women.

VivaGel® BV (BETADINE™ BV) is a novel, non-antibiotic therapy for treatment and prevention of bacterial vaginosis (BV). BV is the most common vaginal condition worldwide and twice as common as thrush. VivaGel® BV (BETADINE™ BV) is an Australian innovation – invented, fully developed and taken through to commercialisation by Starpharma.

BV is a troublesome and often recurrent condition that causes unpleasant vaginal odour and discharge symptoms that have significant social impacts for women. BV has also been associated with a range of other serious reproductive health-related medical problems.

Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to achieve another territory launch of VivaGel® BV with Mundipharma. Asia represents an important market for VivaGel® BV and we’re delighted that our breakthrough product will be available to millions of Asian women who suffer from BV. Mundipharma have a leading position in feminine care in Asia with their successful international brand BETADINE. We look forward to working with Mundipharma on further registrations and launches across the globe.”

Raman Singh, Mundipharma CEO, said: “BETADINE™ BV Gel is a significant addition to the BETADINE product portfolio which continues to evolve to meet women’s everyday health needs across Asia. It is already enabling women across Southeast Asia to access affordable and effective treatment for BV over-the-counter as part of our shared ambition with Starpharma to enhance women’s health’s across Asia.”

Starpharma’s and Mundipharma’s marketing and regulatory teams continue to work actively together on further launches of VivaGel® BV in Mundipharma’s territories. Regulatory activities are underway for multiple countries across Mundipharma’s regions.

About Bacterial Vaginosis (BV)

Bacterial vaginosis is the most common vaginal infection worldwide, and twice as common as thrush. It is a highly recurrent condition with 50-60% of sufferers having it recurrently. BV is caused by an imbalance of naturally occurring bacterial flora (the usual bacteria found in a

woman's vagina). Smoking, the use of some hygiene products and several other risk factors are linked to a higher risk of developing BV. If left untreated, BV can cause a range of serious medical problems including pelvic inflammatory disease, infertility, premature delivery and miscarriage, low birth weights and uterine infection. BV also increases a woman's chance of acquiring HIV and other sexually transmitted infections and increases the likelihood that a woman will infect her partner with these conditions.

TM: BETADINE is a trademark of Mundipharma.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships.

VivaGel®: Starpharma's women's health product - VivaGel® BV is based on SPL7013, astodimer sodium, a proprietary dendrimer. VivaGel® BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem® BV Gel (UK), Betadine BV™ (Europe), Betadine™ BV Gel (Asia) and Fleurstat BVgel (Australia) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel® BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel® condom (an antiviral condom which includes VivaGel® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel® condom has been launched in Japan under Okamoto's 003 brand, and in Australia and Canada under the LifeStyles Dual Protect® brand. The VivaGel® condom is approved in Europe.

DEP® - Dendrimer Enhanced Product®: Starpharma's DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has three internal DEP® products – DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan - in clinical development in patients with solid tumours. Starpharma's partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP® version of one of AstraZeneca's major marketed oncology medicines.

Starpharma.com | [Twitter](https://twitter.com/Starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

Media: WE

Rebecca Wilson
Mob: +61 417 382 391
rwilson@we-worldwide.com

Arthur Chan
+61 2 9237 2805
arthurc@we-worldwide.com

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704

investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.